# US 2024/0174742 A1 · Interferon beta antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0174742 A1
- Document ID: US20240174742A1
- Status: Published application
- Kind: A1
- Application number: 18/511,744
- Filed: 2023-11-16
- Published: 2024-05-30
- Earliest claimed: 2016-04-29
- Assignees: Pfizer Inc.; The Brigham and Women's Hospital, Inc.
- Applicants: Pfizer Inc.; The Brigham and Women's Hospital, Inc.
- Inventors: Stefano V. Gulla; Christine Huard; Janet Elizabeth Buhlmann; Juan Carlos Almagro; Sreekumar R. Kodangattil; Steven A. Greenberg; Edward Roland Lavallie; Eric M. Bennett; Lidia Mosyak; James Perry Hall; Anthony John Coyle
- Web page: https://patentgrep.com/patent/US20240174742A1

## CPC

- C07K 16/249: {Interferons}
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFNβ). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A method of reducing an activity of IFNβ in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the antibody, or antigen-binding fragment thereof, that specifically binds human IFNβ, wherein the antibody or antigen-binding fragment comprises (a) the CDR-H1, CDR-H2, and CDR-H3 sequences of SEQ ID NO: 28, and (b)
i) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 2;
ii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 3;
iii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 4;
iv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 5;
v) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 6;
vi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 7;
vii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 8;
viii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 9;
ix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 10;
x) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 11;
xi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 12;
xii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 13;
xiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 14;
xiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 15;
xv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 16;
xvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 17;
xvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18;
xviii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 19;
xix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 20;
xx) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 21;
xxi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 22;
xxii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 23;
xxiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 24;
xxiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 25;
xxv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 26;
xxvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 27; or
xxvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 1;
or a pharmaceutical composition comprising the antibody or antigen-binding fragment.

### Claim at position 3

-34. (canceled)

### Claim 35

A method of treating a disease, disorder, or condition mediated by, or related to increased activity of IFNβ in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of the antibody, or antigen-binding fragment thereof, that specifically binds human IFNβ, wherein the antibody or antigen-binding fragment comprises (a) the CDR-H1, CDR-H2, and CDR-H3 sequences of SEQ ID NO: 28, and (b)
i) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 2;
ii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 3;
iii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 4;
iv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 5;
v) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 6;
vi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 7;
vii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 8;
viii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 9;
ix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 10;
x) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 11;
xi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 12;
xii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 13;
xiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 14;
xiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 15;
xv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 16;
xvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 17;
xvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 18;
xviii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 19;
xix) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 20;
xx) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 21;
xxi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 22;
xxii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 23;
xxiii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 24;
xxiv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 25;
xxv) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 26;
xxvi) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 27; or
xxvii) the CDR-L1, CDR-L2, and CDR-L3 sequences of SEQ ID NO: 1;
or a pharmaceutical composition comprising the antibody or antigen-binding fragment.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the disease, disorder, or condition mediated by, or related to increased activity of IFNβ is a rheumatic disease.

### Claim 37 (depends on 35)

The method according to claim 35, wherein the disease, disorder, or condition mediated by, or related to increased activity of IFNβ is dermatomyositis (DM).

### Claim 38 (depends on 35)

The method according to claim 35, wherein the disease, disorder, or condition mediated by, or related to increased activity of IFNβ is systemic lupus erythematosus (SLE).

### Claim 39 (depends on 35)

The method according to claim 35, wherein the disease, disorder, or condition mediated by, or related to increased activity of IFNβ is an interferonopathy.

### Claim 40 (depends on 30)

The method according to claim 30, wherein the antibody or antigen-binding fragment comprises (a) the VH sequence of SEQ ID NO: 28, and (b)
i) the VL sequence of SEQ ID NO: 2;
ii) the VL sequence of SEQ ID NO: 3;
iii) the VL sequence of SEQ ID NO: 4;
iv) the VL sequence of SEQ ID NO: 5;
v) the VL sequence of SEQ ID NO: 6;
vi) the VL sequence of SEQ ID NO: 7;
vii) the VL sequence of SEQ ID NO: 8;
viii) the VL sequence of SEQ ID NO: 9;
ix) the VL sequence of SEQ ID NO: 10;
x) the VL sequence of SEQ ID NO: 11;
xi) the VL sequence of SEQ ID NO: 12;
xii) the VL sequence of SEQ ID NO: 13;
xiii) the VL sequence of SEQ ID NO: 14;
xiv) the VL sequence of SEQ ID NO: 15;
xv) the VL sequence of SEQ ID NO: 16;
xvi) the VL sequence of SEQ ID NO: 17;
xvii) the VL sequence of SEQ ID NO: 18;
xviii) the VL sequence of SEQ ID NO: 19;
xix) the VL sequence of SEQ ID NO: 20;
xx) the VL sequence of SEQ ID NO: 21;
xxi) the VL sequence of SEQ ID NO: 22;
xxii) the VL sequence of SEQ ID NO: 23;
xxiii) the VL sequence of SEQ ID NO: 24;
xxiv) the VL sequence of SEQ ID NO: 25;
xxv) the VL sequence of SEQ ID NO: 26;
xxvi) the VL sequence of SEQ ID NO: 27; or
xxvii) the VL sequence of SEQ ID NO: 1.

### Claim 41 (depends on 30)

The method according to claim 30, wherein the antibody or antigen-binding fragment thereof comprises:
(a) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 37;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 38;
(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 39;
(d) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 34;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and
(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 36.

### Claim 42 (depends on 30)

The method according to claim 30, wherein the antibody or antigen-binding fragment thereof comprises a VH that comprises the amino acid sequence of SEQ ID NO: 28 and a VL that comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 43 (depends on 30)

The method according to claim 30, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain that comprises the amino acid sequence of SEQ ID NO: 33 and a light chain that comprises the amino acid sequence of SEQ ID NO: 32.

### Claim 44 (depends on 35)

The method according to claim 35, wherein the antibody or antigen-binding fragment comprises (a) the VH sequence of SEQ ID NO: 28, and (b)
i) the VL sequence of SEQ ID NO: 2;
ii) the VL sequence of SEQ ID NO: 3;
iii) the VL sequence of SEQ ID NO: 4;
iv) the VL sequence of SEQ ID NO: 5;
v) the VL sequence of SEQ ID NO: 6;
vi) the VL sequence of SEQ ID NO: 7;
vii) the VL sequence of SEQ ID NO: 8;
viii) the VL sequence of SEQ ID NO: 9;
ix) the VL sequence of SEQ ID NO: 10;
x) the VL sequence of SEQ ID NO: 11;
xi) the VL sequence of SEQ ID NO: 12;
xii) the VL sequence of SEQ ID NO: 13;
xiii) the VL sequence of SEQ ID NO: 14;
xiv) the VL sequence of SEQ ID NO: 15;
xv) the VL sequence of SEQ ID NO: 16;
xvi) the VL sequence of SEQ ID NO: 17;
xvii) the VL sequence of SEQ ID NO: 18;
xviii) the VL sequence of SEQ ID NO: 19;
xix) the VL sequence of SEQ ID NO: 20;
xx) the VL sequence of SEQ ID NO: 21;
xxi) the VL sequence of SEQ ID NO: 22;
xxii) the VL sequence of SEQ ID NO: 23;
xxiii) the VL sequence of SEQ ID NO: 24;
xxiv) the VL sequence of SEQ ID NO: 25;
xxv) the VL sequence of SEQ ID NO: 26;
xxvi) the VL sequence of SEQ ID NO: 27; or
xxvii) the VL sequence of SEQ ID NO: 1.

### Claim 45 (depends on 35)

The method according to claim 35, wherein the antibody or antigen-binding fragment thereof comprises:
(a) a CDR -H1 comprising the amino acid sequence of SEQ ID NO: 37;
(b) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 38;
(c) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 39;
(d) a CDR-LI comprising the amino acid sequence of SEQ ID NO: 34;
(e) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 35; and
(f) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 36.

### Claim 46 (depends on 35)

The method according to claim 35, wherein the antibody or antigen-binding fragment thereof comprises a VH that comprises the amino acid sequence of SEQ ID NO: 28 and a VL that comprises the amino acid sequence of SEQ ID NO: 1.

### Claim 47 (depends on 35)

The method according to claim 35, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain that comprises the amino acid sequence of SEQ ID NO: 33 and a light chain that comprises the amino acid sequence of SEQ ID NO: 32.
